Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Mostrar outras versões (1)

Multiple myeloma is a B-cell malignancy characterized by the accumulation of plasma cells in the bone marrow and the development of osteolytic bone disease. The present study demonstrates that myeloma cells express the critical osteoclastogenic factor RANKL (the ligand for receptor activator of NF-k...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Croucher, P, Shipman, C, Lippitt, J, Perry, M, Asosingh, K, Hijzen, A, Brabbs, A, van Beek, E, Holen, I, Skerry, T, Dunstan, C, Russell, G, Van Camp, B, Vanderkerken, K
Formato:	Journal article
Idioma:	English
Publicado em:	2001

Registros relacionados

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
por: Croucher, P, et al.
Publicado em: (2001)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
por: Croucher, P, et al.
Publicado em: (2000)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
por: Croucher, P, et al.
Publicado em: (2001)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
por: Croucher, P, et al.
Publicado em: (2003)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
por: Croucher, P, et al.
Publicado em: (2002)

Osteoprotegerin and the development of myeloma bone disease
por: Croucher, P, et al.
Publicado em: (2004)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
por: Shipman, C, et al.
Publicado em: (2000)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
por: Vanderkerken, K, et al.
Publicado em: (2003)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
por: Shipman, C, et al.
Publicado em: (2000)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
por: Shipman, C, et al.
Publicado em: (2002)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
por: De Leenheer, E, et al.
Publicado em: (2004)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
por: Shipman, C, et al.
Publicado em: (2002)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
por: Croucher, P, et al.
Publicado em: (2003)

Role of osteoprotegerin (OPG) in cancer.
por: Holen, I, et al.
Publicado em: (2006)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
por: Croucher, P, et al.
Publicado em: (2002)

Bisphosphonates--mechanisms of action in multiple myeloma.
por: Shipman, C, et al.
Publicado em: (2000)

Bisphosphonates and in vivo models of multiple myeloma - Reply
por: Shipman, C, et al.
Publicado em: (2001)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
por: Shipman, C, et al.
Publicado em: (2000)

The role of osteoprotegerin in breast and prostate cancer
por: Holen, I, et al.
Publicado em: (2002)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
por: De Leenheer, E, et al.
Publicado em: (2002)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
por: Shipman, C, et al.
Publicado em: (2002)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
por: Shipman, C, et al.
Publicado em: (2003)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
por: Holen, I, et al.
Publicado em: (2002)

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
por: Eaton, C, et al.
Publicado em: (2004)

RANKL/RANK/osteoprotegerin system as novel therapeutic target in the treatment of primary bone tumors and osteolytic metastases
por: Anđelković Zlatibor, et al.
Publicado em: (2004-01-01)

Osteocyte CIITA aggravates osteolytic bone lesions in myeloma
por: Huan Liu, et al.
Publicado em: (2022-06-01)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
por: Mueller, G, et al.
Publicado em: (2004)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
por: Mueller, G, et al.
Publicado em: (2004)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
por: Edwards, C, et al.
Publicado em: (2007)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
por: Holen, I, et al.
Publicado em: (2002)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
por: Eaton, C, et al.
Publicado em: (2004)

Osteolytic lesions: Multiple myeloma or prostate cancer?
por: Akshitha Devaraj, MBBS, et al.
Publicado em: (2023-04-01)

Preventing osteolytic lesions and osteomyelitis in multiple myeloma
por: Aiken Dao, et al.
Publicado em: (2022-12-01)

Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma
por: Dongyeop Shin, et al.
Publicado em: (2024-01-01)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
por: Locklin, R, et al.
Publicado em: (2005)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
por: Waterman, E, et al.
Publicado em: (2007)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
por: Dongzheng Gai, et al.
Publicado em: (2022-09-01)

Multiple myeloma presenting as a massive osteolytic lesion at the clivus
por: Domingos Sousa, et al.
Publicado em: (2020-11-01)

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
por: Dirk Hose, et al.
Publicado em: (2024-12-01)

A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo
por: Lwin, S, et al.
Publicado em: (2017)